These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29190906)

  • 1. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.
    Hong J; Kim SJ; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Lee HS; Yun HJ; Lee SI; Kim MK; Yi JH; Lee JH; Kim WS; Suh C
    Oncotarget; 2017 Nov; 8(54):92171-92182. PubMed ID: 29190906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
    Salas MQ; Mercadal S; Domingo Domenech E; Oliveira AC; Encuentra M; Climent F; Andrade Campos M; Aguilera C; Fernández de Sevilla A; Sureda A; González-Barca E
    Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
    Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
    Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
    Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
    Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
    Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
    Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
    Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
    [No Abstract]   [Full Text] [Related]  

  • 8. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of GELTAMO-IPI for Patients with Diffuse Large B-cell Lymphoma].
    Feng YX; Su LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):98-103. PubMed ID: 33554804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study.
    Hwang HS; Kim M; Park CS; Yoon DH; Suh C; Huh J; Go H
    Cancer Res Treat; 2021 Jan; 53(1):270-278. PubMed ID: 32972046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
    Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
    Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
    Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
    BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.
    Jiang C; Teng Y; Zheng Z; Zhou Z; Xu J
    Quant Imaging Med Surg; 2021 Jun; 11(6):2509-2520. PubMed ID: 34079720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.
    Jelicic J; Juul-Jensen K; Bukumiric Z; Runason Simonsen M; Roost Clausen M; Ludvigsen Al-Mashhadi A; Schou Pedersen R; Bjørn Poulsen C; Ortved Gang A; Brown P; El-Galaly TC; Larsen TS
    Cancer Med; 2024 Jun; 13(12):e7239. PubMed ID: 38888359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy.
    Jelicic J; Todorovic Balint M; Sretenovic DA; Balint B; Perunicic Jovanovic M; Andjelic B; Vukovic V; Djurasinovic V; Bila J; Pavlovic M; Smiljanic M; Mihaljevic B
    Neoplasma; 2015; 62(6):988-95. PubMed ID: 26458307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
    Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Med Oncol; 2017 Feb; 34(2):29. PubMed ID: 28083854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.